Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses

[1]  J. Reynolds,et al.  Fractalkine Elicits Chemotactic, Phenotypic, and Functional Effects on CX3CR1+CD27− NK Cells in Obesity-Associated Cancer , 2021, The Journal of Immunology.

[2]  Yu Zhao,et al.  B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma , 2021, Annals of translational medicine.

[3]  C. Preußer,et al.  Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles , 2021, International journal of molecular sciences.

[4]  Lucas Ferrari de Andrade,et al.  NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells , 2020, Clinical & translational immunology.

[5]  J. Ajani,et al.  LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study , 2020 .

[6]  S. Utturkar,et al.  TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation , 2020, Cancers.

[7]  Joseph Cursons,et al.  The cancer–natural killer cell immunity cycle , 2020, Nature Reviews Cancer.

[8]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[9]  I. Ghobrial,et al.  Immunotherapy for hematological malignancies. , 2019, Journal of life sciences.

[10]  É. Vivier,et al.  Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.

[11]  C. Porta,et al.  Deficient Natural Killer Cell NKp30‐Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma , 2019, Hepatology.

[12]  J. O’Sullivan,et al.  Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells , 2019, Pharmaceuticals.

[13]  Joseph Cursons,et al.  The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. , 2019, Trends in immunology.

[14]  Natural killer cells for cancer immunotherapy: a new CAR is catching up , 2019, EBioMedicine.

[15]  R. Sun,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[16]  Ying Chen,et al.  The B7 Family Member B7-H6: a New Bane of Tumor , 2018, Pathology & Oncology Research.

[17]  A. Santoni,et al.  Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance , 2017, Front. Immunol..

[18]  Yuhchyau Chen,et al.  Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition , 2017, Scientific Reports.

[19]  B. Edil,et al.  Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions , 2017, Cancer Immunology, Immunotherapy.

[20]  J. Reynolds,et al.  Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. , 2017, Journal of thoracic disease.

[21]  S. Granjeaud,et al.  NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia , 2017, Oncotarget.

[22]  J. Blay,et al.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients , 2017, Oncoimmunology.

[23]  Meijuan Huang,et al.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer , 2017, Oncoimmunology.

[24]  N. Lynam‐Lennon,et al.  MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype , 2016, Oncotarget.

[25]  J. Reynolds,et al.  The microenvironment of visceral adipose tissue and liver alter natural killer cell viability and function , 2016, Journal of leukocyte biology.

[26]  K. Straif,et al.  Body Fatness and Cancer--Viewpoint of the IARC Working Group. , 2016, The New England journal of medicine.

[27]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[28]  M. Caligiuri,et al.  Obesity, Inflammation, and Cancer. , 2016, Annual review of pathology.

[29]  J. O’Sullivan,et al.  Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. , 2016, Cancer letters.

[30]  R. Sun,et al.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6* , 2015, The Journal of Biological Chemistry.

[31]  C. Viswanathan,et al.  Natural killer cells: In health and disease. , 2015, Hematology/oncology and stem cell therapy.

[32]  L. Zitvogel,et al.  Natural killer cell mediated immunosurveillance of pediatric neuroblastoma , 2015, Oncoimmunology.

[33]  D. Pardoll.  Distinct mechanisms of tumor resistance to NK killing: of mice and men. , 2015, Immunity.

[34]  L. Zitvogel,et al.  Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients , 2015, Science Translational Medicine.

[35]  G. Tabellini,et al.  B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape , 2015, Oncoimmunology.

[36]  P. Altevogt,et al.  Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. , 2014, Cancer research.

[37]  J. Reynolds,et al.  Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research. , 2013, Nutrition research.

[38]  Lan-Jun Zhang,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[39]  A. Jha,et al.  Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. , 2012, Blood.

[40]  T. Niki,et al.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. , 2012, Blood.

[41]  P. Sun,et al.  Natural killer cell‐produced IFN‐γ and TNF‐α induce target cell cytolysis through up‐regulation of ICAM‐1 , 2012, Journal of leukocyte biology.

[42]  P. Johnston,et al.  Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer , 2010, Clinical Cancer Research.

[43]  H. Ljunggren,et al.  Down-regulating Dnam-1 on Nk Cells Cd155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing , 2022 .

[44]  Eric Vivier,et al.  Natural Killer Cell Signaling Pathways , 2004, Science.

[45]  A. Thiel,et al.  The small subset of CD56brightCD16– natural killer cells is selectively responsible for both cell proliferation and interferon‐γ production upon interaction with dendritic cells , 2004, European journal of immunology.

[46]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[47]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.